Can you imagine that FDA's demand for a complicated molecule such as Copaxone would be less (without bioequivalence) than for a simple compound such as aspirin?
The FDA sometimes grants a waiver of the bioequivalence requirement for generic drugs that are injected.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.